Clinical Trials > All Submitted Clinical Trials
It is not the intention of the Cholangiocarcinoma Foundation to provide specific medical advice. We provide website users with information to help them better understand their health conditions and the current approaches related to prevention, diagnosis, treatment and supportive care. You are urged to always seek the advice of your physician or other qualified healthcare provider.
This Phase 2 study will be conducted in conjunction with the companion harvest protocol protocol in patients with measurable disease who have lesions that can be resected or biopsied for Tumor Infiltrating Lymphocyte(TIL) growth. The Treatment Phase begins once the cells exceed the cell growth and potency requirements in the companion protocol.Read More
The purpose of this study is to test whether Xermelo®, when given with chemotherapy (cisplatin/gemcitabine) that is used as a standard treatment, will have an effect on the growth of biliary tract cancer (BTC) tumors. Safety of using these drugs in combination will also be evaluated. Xermelo® is not currently approved for use in BTC.Read More
This is a multicenter, open-label, uncontrolled, repeat-dose phase 1/2a study designed to evaluate the safety profile and to determine the Recommended Dose of GNS561 in patients with advanced advanced primary liver cancer (Hepatocarcinoma, Intrahepatic Cholangiocarcinoma). This study consists of 2 parts: escalation and expansion phase.Read More
This is a trial of combining a HDAC inhibitor and a PD1 inhibitor (immunotherapy drug) to make cholangiocarcinoma more sensitive to immunotherapy. This is based on laboratory data that shows HDAC inhibitors can make tumors more sensitive to immunotherapy.Read More
This study is a dose escalation study to determine the safety and tolerability of Ceramide NanoLiposome in patients with advanced solid tumors.Read More